Standing Order
All companies

Biotech

Kymera Therapeutics, Inc.

KYMRNASDAQpure-play
Market cap$9.8B
Conviction3/ 5
HQWatertown, MA
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$115.31

+167.4%

Thesis

Kymera is a leading targeted-protein-degradation company applying its platform to immunology and inflammation — degrading disease-driving proteins (STAT6, IRAK4) that conventional small molecules struggle to drug, aiming for oral therapies that compete with injectable biologics. Pharma partnerships (e.g. Sanofi) have validated the platform and helped fund it.

The investment case is platform breadth: one degradation chemistry reused across many immunology targets, with oral convenience as the commercial wedge against biologics. Risks: clinical-stage with the binary readout risk that entails, competition across the degrader field, and value spread across early programs rather than an approved product.

Catalysts

  • STAT6 degrader clinical readouts in atopic dermatitis / immunology
  • IRAK4 and follow-on program progress
  • Partnership economics and option exercises
  • Oral-vs-biologic differentiation data

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 2
    Trial readoutClinicalTrials.gov

    Kymera completes Phase 1 first-in-human study of KT-579 in healthy adults (NCT07412288).

  • Oct 29
    Financial resultsSEC

    Kymera Therapeutics filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.

  • Oct 7
    Trial initiationClinicalTrials.gov

    Kymera starts Phase 2 long-term extension study of KT-621 in prior asthma trial participants (NCT07677059, recruiting)

  • Oct 6
    Trial initiationClinicalTrials.gov

    Kymera initiates Phase 2 trial of KT-621 in moderate to severe eosinophilic asthma (NCT07323654, recruiting).

  • Oct 6
    Trial initiationClinicalTrials.gov

    Kymera updates Phase 2 trial NCT07217015 of KT-621 in moderate to severe atopic dermatitis to ACTIVE_NOT_RECRUITING status.

  • Aug 17
    Trial initiationClinicalTrials.gov

    Kymera initiates Phase 2 trial (NCT07323654) of KT-621 in moderate to severe eosinophilic asthma; recruiting status as of 2026-08-17.

  • Aug 5
    Financial resultsSEC

    Kymera Therapeutics files 8-K (items 2.02, 9.01) disclosing financial results.

  • Jul 27
    LeadershipSEC

    8-K filed with items 5.02, 7.01, 9.01 covering officer or director changes and related exhibits.

Not financial advice — research and opinion only. Disclosures